Biotechnology & Pharmaceuticals

The continual need for improved therapeutics for patients, biotech and pharma companies are making enormous strides across conditions from oncology and neurodegeneration to immune diseases.Traditional small molecules and established monoclonal antibodies, along with advanced modalities including cell/gene therapy, require scientific, in addition to financial, expertise to fully capture the value of these technologies and appreciate the science that drives them. 

Given the extended timeline to get drugs to market and the rapidly changing commercial landscape with generic and biosimilar entrants, strategic transactions occur at all stages from discovery through commercial. With 35+ years of experience, our team knows how to position biotech and pharma companies with differentiated mechanisms, proven clinical efficacy, and established commercial markets for strategics to expand their portfolio and enter new therapeutic areas.

Whether seeking asset partnerships or an M&A transaction, our dedicated life sciences team effectively communicates the value of biotech and pharma businesses and their assets to strategic counterparties. 450+ completed transactions prove we capture the premium valuations that technologies command.